Background
In the management of anesthesia during cardiac surgery, it is important
to stably maintain the patient’s cardiovascular function throughout the
operation. Therefore, it is necessary to carefully evaluate the
patient’s cardiovascular function before surgery, monitor their general
condition, and choose sedatives and analgesics carefully during
anesthesia management. On the other hand, remimazolam, an
ultra-short-acting benzodiazepine, has been available for use in Japan
since 2020 [1]. This drug has a short half-life and causes minimal
circulatory depression [2], making it a suitable sedative for
patients with decreased cardiac function. In this report, we used
remimazolam safely in the anesthesia management of coronary artery
bypass graft (CABG) surgery, and present our findings. Written informed
consent was obtained from the patient to publish this case report.